SCHEMBL26494239

SCHEMBL26494239

CC(C)C1CCC(C(=O)N2CCC(CCC3CCN(C(C)C)CC3)CC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 7/20 0.45
SIGMAR1 Q99720 1/20 0.44
TP53 P04637 1/20 0.42
HPGD P15428 3/20 0.42
POLB P06746 1/20 0.42
PKM P14618 1/20 0.41
HTT P42858 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
KCNH2 Q12809 2/20 0.39
CYP2D6 P10635 1/20 0.39
HSD11B1 P28845 2/20 0.38
CHRNB2 P17787 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA4 P43681 1/20 0.37
CHRNB3 Q05901 1/20 0.37
CHRNA6 Q15825 1/20 0.37
ALDH1A1 P00352 2/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26494244 0.94 HPGD (0.46) HRH3SIGMAR1TP53HPGDPOLB
SCHEMBL26494227 0.91 HRH3 (0.45) HRH3SIGMAR1TP53HPGDPOLB
SCHEMBL26494236 0.88 HRH3 (0.43) HRH3SIGMAR1TP53HPGDPOLB
SCHEMBL26494241 0.86 HRH3 (0.41) HRH3SIGMAR1TP53HPGDPOLB
SCHEMBL26295685 0.85 HRH3 (0.43) HRH3SIGMAR1TP53HPGDPOLB
SCHEMBL26494224 0.85 HRH3 (0.55) HRH3SIGMAR1HPGDPOLBHTT
SCHEMBL26295653 0.84 HRH3 (0.53) HRH3KCNH2CYP2D6
SCHEMBL26295692 0.83 HRH3 (0.41) HRH3SIGMAR1HPGDPOLBPKM
SCHEMBL25074969 0.82 SMN1; SMN2 (0.52) HRH3SIGMAR1KCNH2HSD11B1ALDH1A1
SCHEMBL26494238 0.82 HPGD (0.44) SIGMAR1TP53HPGDPOLBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. 2023-05-04 US disclosed
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, BCL9, CRBN HRH3 3222/4885SIGMAR1 3987/4885TP53 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.